Aravive Announces Phase 3 AXLerate-OC Study Of Batiraxcept In Platinum-Resistant Ovarian Cancer Did Not Meet Primary Endpoint
Portfolio Pulse from Benzinga Newsdesk
Aravive announced that its Phase 3 AXLerate-OC study of Batiraxcept in platinum-resistant ovarian cancer did not meet its primary endpoint.
August 04, 2023 | 12:21 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Aravive's Phase 3 study of Batiraxcept did not meet its primary endpoint, which could negatively impact the company's stock.
The failure of a Phase 3 study is a significant setback for any pharmaceutical company as it indicates that the drug may not be effective. This could lead to a decrease in investor confidence and a potential drop in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100